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Spinocerebellar ataxiaFine tuning of integrated mitochondrial functions is essential in neurons and rationalizes why mitochondrial
dysfunction plays an important pathogenic role in neurodegeneration. Mitochondria can contribute to
neuronal cell death and axonal dysfunction through a plethora of mechanisms, including low ATP levels,
increased reactive oxygen species, defective calcium regulation, and impairment of dynamics and transport.
Recently, mitochondrial proteases in the inner mitochondrial membrane have emerged as culprits in several
human neurodegenerative diseases. Mitochondrial proteases degrade misfolded and non-assembled
polypeptides, thus performing quality control surveillance in the organelle. Moreover, they regulate the
activity of speciﬁc substrates by mediating essential processing steps. Mitochondrial proteases may be
directly involved in neurodegenerative diseases, as recently shown for the m-AAA protease, or may regulate
crucial mitochondrial molecules, such as OPA1, which in turn is implicated in human disease. The
mitochondrial proteases HTRA2 and PARL increase the susceptibility of neurons to apoptotic cell death. Here
we review our current knowledge on how disturbances of the mitochondrial proteolytic system affect
neuronal maintenance and axonal function.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are interconnected dynamic organelles that serve
pivotal functions in neurons, which depend entirely on aerobic
metabolism [1,2]. ATP production is required to maintain ionic
gradients and sustain neuronal excitability, and is essential for
neurotransmission. Mitochondrial derived reactive species may
function as signals in synaptic plasticity, learning and memory.
Furthermore, mitochondria regulate Ca++ homeostasis and dynamics
and are key players in apoptotic and necrotic cell death programs. In
highly polarized cells as neurons, mitochondrial function is strictly
coupled to efﬁcient transport mechanisms, which ensure delivery of
the organelles to dendritic spines and growth cones, sites of high
energetic need. Mitochondrial transport and distribution in neurons is
a complex and crucial process,modulated by the ability ofmitochondria
to undergo fusion and ﬁssion events, by synaptic activity, and still
unknown intracellular signals [3,4]. Given this functional complexity,
not surprisingly mitochondrial dysfunction plays a central role in
several neurodegenerative diseases.Mutations inmt-DNA are frequent-
ly associated with neurological symptoms such as ataxia, external
ophthalmoplegia, and peripheral neuropathy. Moreover, mutations in
nuclear-encoded mitochondrial proteins often lead to progressive
neuronal death [5,6].Molecular Pathology, Istituto
Italy. Tel.: +39 0223942614;
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ll rights reserved.Two independent genomes, the mitochondrial and the nuclear
genome, are required for mitochondrial biogenesis. Communication
mechanisms coordinate the transcriptional activity of the two genomes
in response to metabolic demands [7]. To overcome a possible
unbalance between nuclear-encoded andmitochondrial-encoded poly-
peptides,mitochondria havedeveloped efﬁcient quality control systems
of newly imported mitochondrial proteins [8,9]. On one hand,
chaperones assist the folding of imported polypeptides and the
assembly of protein complexes, on the other hand proteases degrade
misfolded polypeptides and get rid of excess protein components
lacking assembly partners. Proteases serve also as processing enzymes,
thus increasing the complexity of the mitochondrial proteome.
Mitochondrial proteases have therefore all the characteristics for
being crucial regulators of mitochondrial function. This is illustrated by
the emerging role of disturbances ofmitochondrial proteolysis in neuro-
degenerative conditions. We review here the current evidences that
mitochondrial proteases candirectly or indirectly causedegenerationsof
axons and neurons.2. Neurodegenerative diseases due to defects of them-AAA protease
2.1. The m-AAA protease: from protein quality control to regulatory
functions
Them-AAA protease is a key component of a quality control system
that mitochondria employ to conduct the surveillance of proteins of the
inner membrane and to degrade in a selective manner non-assembled
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described and studied in Saccharomyces cerevisiae. In this organism the
m-AAA protease is a hetero-oligomeric complex composed by highly
homologous subunits (Yta10p and Yta12p) [10]. The human m-AAA
protease has a native molecular mass of approximately 900 kDa and is
composed of paraplegin and AFG3L2 [11,12] (Fig. 1B). Yeast and
mammalian subunits of the m-AAA protease contain a mitochondrial
targeting sequence, two transmembrane domains, and a AAA (triple-A,
ATPase Associatedwith various cellular Activities) domain followed by a
metal-dependent proteolytic domain (Fig. 1A). The AAA domain deﬁnes
the superfamily of AAA+ proteins, a group of ATPases with common
ancestry, characterized by a conserved region of 220–250 amino acids,
theAAA cassette [13]. The protease owes its name to the presence of this
domain, and to the topology of the proteolytic domain that is exposed
towards the matrix space of mitochondria. Yeast and mammalian
mitochondria also contain an i-AAA protease composed of the homo-
oligomeric Yme1 containing complex, with an opposite orientation in
mitochondria (i stands for intermembrane space) (Fig. 1). These
proteases actively extract transmembrane segments and pull solvent-
exposed domains across the membrane, before exerting proteolytic
activity [14,15]. The topology of substrate proteins determines which
protease is involved in degradation, although overlapping substrate
speciﬁcity has been described in yeast [14,16]. Misfolded or damaged
proteins are degraded to peptides, which are then either exported from
the organelle or degraded further to amino acids by various oligopepti-
dases. Inactivationof them-AAAprotease in yeast leads to the inability to
grow on non-fermentable carbon sources, reﬂecting an important role
during mitochondrial biogenesis [10,17]. Known substrate polypeptides
of the yeast m-AAA protease include respiratory complex components,Fig. 1. Structure and topology of the proteases described in this review. A. Schematic repr
mitochondrial targeting sequence; TM, transmembrane domain; AAA, triple-A domain (ATPa
domain; CC, coiled coil, IBM, inhibitor of apoptosis (IAP)-binding motif; S1 protease, trypsin
human proteases in mitochondria. Abbreviations: IMS, inter membrane space; IM, inner mand F1Fo ATPase subunits [10,17], while the physiological substrates of
the mammalian enzyme are still largely unknown.
A more recent role attributed to the yeast m-AAA protease
involves its ability to mediate proteolytic maturation of speciﬁc
proteins. The m-AAA protease processes the mitochondrial ribosomal
components MrpL32 [18]. This maturation is a prerequisite for
MrpL32 incorporation into preassembled mitochondrial ribosomes
[18]. In absence of MrpL32 maturation, severe defects of mitochon-
drial protein synthesis occur, explaining respiratory deﬁciencies of
yeast cells lacking Yta10p or Yta12p [18]. This ﬁnding opened up a
complete new perspective, demonstrating a regulatory role for the
protease and suggesting that identiﬁcation of speciﬁc substrates is a
key step to understand consequences of the protease dysfunction.
In contrast to yeast, human cells possess twom-AAA isoenzymes, a
hetero-oligomeric complex made up of paraplegin and the AFG3L2
protein and a homo-oligomeric complex formed by AFG3L2 alone [19]
(Fig. 1B). Both the hetero-oligomeric paraplegin-AFG3L2 complex and
the homo-oligomeric AFG3L2 complex are able to process the
ribosomal subunit MrpL32, and to mediate degradation of non-native
membrane proteins in a reconstituted yeast system, demonstrating
functional complementation [18,19]. Moreover, these experiments
highlight the functional redundancy between the homo-oligomeric
and hetero-oligomeric mammalian m-AAA proteases.
2.2. m-AAA protease subunits, paraplegin and AFG3L2, are involved in
different neurodegenerative diseases
Paraplegin was the ﬁrst subunit of the m-AAA protease associated
to a human neurodegenerative disease [12]. The SPG7 gene, mappingesentation of domains of the proteases mentioned in this review. Abbreviations: MTS,
se Associated with various cellular Activities); M41 protease, metal binding proteolytic
-like protease domain, PDZ, PDZ domain. B. Illustration of localization and topology of
embrane; M, matrix.
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mutated in a family affected by an autosomal recessive form of
hereditary spastic paraplegia (HSP) [12]. This disease is characterized
by progressive spasticity and weakness of the lower limbs due to the
relentless retrograde degeneration of cortical motor neuron axons
[20] (Fig. 2). HSP is genetically heterogeneous, and SPG7 accounts for
1.5 to 4% of recessive familial cases [21,22]. However, a recent study in
98 Dutch patients with sporadic adult-onset upper motor neuron
syndromes revealed a high frequency of mutations in the SPG7 gene,
responsible for about 11% of these cases [23].
SPG7 mutated alleles are clearly loss-of-function, and the patho-
genesis of the disease can therefore be ascribed to the lack of the
hetero-oligomeric paraplegin–AFG3L2 complex [12,22,24–28]
(Fig. 2). Interestingly, in different HSP families analyzed for SPG7,
the mutation was found in only one allele [22,24]. It is still unclear
whether the second mutation escaped identiﬁcation, or whether a
dominant effect of certain mutations or digenic inheritance of the
disease could occur in some cases. One study excluded mutations in
AFG3L2 [24].
Recently, the AFG3L2 gene has been linked to a form of spinocer-
ebellar ataxia (Franco Taroni, personal communication and [29,30])
(Fig. 2). Spinocerebellar ataxias are a heterogeneous group of
neurological disorders clinically characterized by loss of balance,
progressive gait and limb ataxia, and dysarthria and caused by degen-
eration of the cerebellum and its afferent and efferent connections [31].
A novel SCA locus (SCA28) was mapped on chromosome 18p11.22–
q11.2 in a four-generation Italian family with an autosomal dominant
form of cerebellar ataxia (ADCA), deﬁning a critical region that included
the AFG3L2 gene [32]. Ten different missense mutations were found in
familial and sporadic ADCA patients [29,30]. Strikingly, mutations hit
conserved residues in the peptidase domain, suggesting a possible gain-
of-function or dominant-negative effect.Fig. 2. Phenotypes associated to mutations in m-AAA protease subunits in human and mou
corticospinal axons, while heterozygous missense mutations in AFG3L2 cause spinocerebe
progressive reduction of the levels of m-AAA proteases subunits, and ranges from late-onse
involving also the cerebellum, up to severe developmental defects in brain, spinal cord, an
central mitochondrion. Missense mutations are indicated by the lightning symbol. For the
Abbreviations, L1, AFG3L1; L2, AFG3L2; P, paraplegin.In contrast to paraplegin mutations that affect only the hetero-
oligomeric complex, mutations in AFG3L2 impact both m-AAA
isoenzymes (Fig. 2). This also rationalizes the fact that recessive
mutations of paraplegin cause a rather mild phenotype, while only
heterozygous missense mutations of AFG3L2 are tolerated. Remarkably,
from a clinical point of view, phenotypes of patients carryingmutations
in one or the other subunit have some points of overlap. Patients with
mutations in SPG7 often show a complicated form of HSP associated
with cerebellar atrophy and ataxic signs, and careful examination ofHSP
patients for signs of cerebellar dysfunction can help identifying patients
with SPG7 involvement [22–24,26,27]. Similarly, SCA28 patients
frequently present lower limb hyperreﬂexia [33]. It will be of interest
to explore the possibility that digenic inheritance of mutations in
AFG3L2 and SPG7may underlie some forms of cerebellar ataxia, spastic
paraparesis, or other neurological phenotypes.
2.3. Pleiotropic roles of m-AAA proteases in neurodevelopment and
neurodegeneration
The involvement ofm-AAA proteases in degeneration of spinal and
peripheral axons and in cerebellar dysfunction is nicely recapitulated
in mouse models (Fig. 2). Moreover, mouse genetics has clearly
indicated that these enzymes are required for development of axonal
and dendritic processes in several brain areas (Fig. 2).
Spg7−/−mice were generated by deleting the ﬁrst two exons of the
gene by homologous recombination [34]. They showed motor impair-
ment at the rotarod test at 4.5 months and developed a pronounced
scoliosis and abnormal movements of the hindlimbs with increasing
age. Neuropathologic analysis revealed a late-onset retrograde axonal
degeneration in long descending motor spinal tracts, long ascending
sensory spinal tracts, peripheral and optic nerves, resembling the HSP
phenotype [34].se. In humans (on the left), mutations on both alleles of SPG7 lead to degeneration of
llar ataxia. In the mouse (right), the severity of the phenotype increases along with
t neurodegeneration of spinal and peripheral axons, to early-onset neurodegeneration
d muscle. Residual subunits of m-AAA proteases in each condition are depicted in the
sake of simplicity only homo-oligomeric AFG3L1 and AFG3L2 complexes are shown.
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AFG3L2 protein are affected by a severe early-onset neurological
phenotype [35]. Two different mouse models are currently available.
The ﬁrst one is the spontaneous mouse mutant paralysé, ﬁrst observed
at the Pasteur Institute and recently found to carry a C to G transversion
causing the substitution of an arginine by a glycine (R389G) in the
conserved AAA domain of AFG3L2 (Afg3l2par) [35,36]. A null Afg3l2
mouse model originated at the Jackson laboratories after ecotropic
murine leukemia proviral reinsertion in the MEV/2TyJ strain in intron
14 of the gene (Afg3l2Emv66). The reinsertion causes a premature stop
codon insertion and the following instability of the protein product [35].
Both mouse models are indistinguishable from control littermates at
birth, but they fail to grow and do not survive over 16 days of age, when
they are completely paralyzed [35–37]. The phenotype is due to severe
defects in neural development, with a retardation of myelination and
the absence of large calibre axons in sciatic nerve and spinal cord
[35,37]. Interestingly, Purkinje cellswere normal in number but failed to
develop a branched dendritic tree [35,38]. Afg3l2 deﬁcient mice have
still residual m-AAA protease activity, since the murine protease is
composed by three different subunits: paraplegin, AFG3L2 and AFG3L1.
The last subunit is a pseudogene in humans [39]. Coimmunoprecipita-
tion experiments demonstrated that all the subunits are able to interact
with each other and that AFG3L1 can form a homo-oligomeric complex
that rescues all the phenotypes of yeast cells deﬁcient of Yta10 or Yta12,
similarly to Afg3l2 [19]. Although Afg3l1 is poorly expressed in the adult
brain [19,38], it is conceivable that the complete absence of m-AAA
proteases might be embryonic lethal.
The homo-oligomeric AFG3L2 complex plays also an important
role in preventing neurodegeneration in the adult brain [38].
Heterozygous Afg3l2 mice appear normal at birth and do not show a
remarkable phenotype up to 3 months of age [38]. However, future
studies are required to exclude the appearance of degenerative
phenotypes in the spinal axons and/or in the cerebellum at late ages.
Mice carrying only one functional allele of Afg3l2 in a null background
of Spg7 showed instead a severe neurological phenotype from
6 weeks of age, characterized by reduced cage activity, loss of balance,
and frank uncoordinated gait, a phenotype highly reminiscent of
cerebellar ataxia. Later, they lost signiﬁcant weight, became immobile,
and ﬁnally died within the 4th month of life [38]. These animals
displayed a remarkable acceleration of the axonal phenotype of Spg7
knock-out mice in the spinal cord and sciatic nerve, revealing a
signiﬁcant redundancy of the homo-oligomeric and hetero-oligomeric
m-AAA isoenzymes in adult neurons in vivo. However, at variance
with the paraplegin-deﬁcient mice, they also manifested an important
loss of Purkinje cells and their afferent and efferent connections,
together with prominent reactive astrogliosis, accounting for the ataxic
phenotype [38]. Moreover, pyramidal hippocampal neurons speciﬁcally
in the CA3 ﬁeld degenerated, stressing the concept that different
neurons respond to reduced levels of them-AAA subunitswith different
thresholds [38].
Afg3l2 and Spg7 are expressed at different levels in the brain and,
while the Afg3l2 transcript is ubiquitous and highly expressed, Spg7
is enriched in large neurons, such as pyramidal cortical neurons and
Purkinje cells [19,38]. Thus some neurons may be more depen-
dent than others on the action of the hetero-oligomeric protease.
Moreover, the different biochemical properties of paraplegin and
AFG3L2 may in part explain the various severity and spatio-temporal
pattern of neuronal degeneration in case of mutations in one or the
other subunit. Crucial questions that need to be addressed are
whether neurons are differently affected purely based on their supply
of individual subunits, whether neuronal-speciﬁc substrates exist
driving a certain pattern of degeneration, and ﬁnally whether hetero-
and homo-oligomeric complexes have also specialized non-redun-
dant functions.
All together, genetic ﬁndings in human and mice underline the
requirement of an efﬁcient surveillance system by the m-AAAprotease in neuronal mitochondria to prevent neuronal and axonal
degeneration, and to allow normal neural development (Fig. 2).
2.4. Understanding the pathogenesis of m-AAA protease-linked diseases
Pathogenic pathways potentially involved in conditions associated
to dysfunction of the m-AAA proteases are summarized in Fig. 3.
Axonal and neuronal degeneration in mice deﬁcient for m-AAA
protease subunits clearly associated with the appearance of structurally
abnormal mitochondria. Hypertrophic, altered mitochondria with
disrupted cristae were detected in synaptic terminal of spinal axons of
paraplegin-deﬁcient mice already at 4.5 months, exactly at the time of
onset of motor impairment, and then accumulated in distal affected
axons [34]. Similar ultrastructural abnormal mitochondria were
observed in cell bodies of motoneurons and Purkinje cells of Afg3l2
mutants, and in Purkinje cells of Spg7−/− Afg3l2Emv66/+ mice [35,38].
Remarkably, the restoration of paraplegin expression in sciatic nerve
mitochondria, using AAV vectors expressing the Spg7 cDNA delivered
intramuscularly, rescued the mitochondrial morphology, suggesting
that these alterations are in principle reversible [40]. The re-expression
of paraplegin also improved neuropathological changes and motor
performance of Spg7−/−mice [40].
Which are the downstream effects of these mitochondrial altera-
tions? Paraplegin-deﬁcient mice are characterized by a pure axono-
pathy without cell death. In these mice the most striking phenotype is
the appearance of axonal swellings that are loadedwith neuroﬁlaments
and organelles, particularly the abnormal mitochondria [34]. Impair-
ment of retrograde transport was also evident in old Spg7−/−mice [34].
Degeneration of parallel ﬁbers with terminal swellings was observed in
the cerebellum of Spg7−/− Afg3l2Emv66/+ mice [38]. All together this
points to impairment of axonal transport as a common pathogenic
bottleneck, leading ﬁrst to axonal degeneration and then to cell death.
The two most affected neuronal types in m-AAA protease diseases are
characterized either by the longest axons (corticalmotor neurons) or by
the most elaborate dendritic tree (Purkinje cells), and in both cases
depend heavily on proper and regulated mitochondrial transport and
distribution. This idea is also supportedby the involvementof trafﬁcking
genes in several other forms of HSP [41].
Transport of mitochondria along axons and dendrites may be ﬁrst
affected because of mechanical clogging owing to the increased
mitochondrial dimensions and then be further worsened by ener-
getic deﬁciency, creating a vicious cycle. Several evidences suggest
that m-AAA protease-depleted mitochondria may have a reduced
capability to adapt to high energetic demands. Fibroblasts from some
SPG7 mutated HSP patients had depolarized mitochondria, reduced
complex I activity and ability to synthesize ATP, together with an
increased susceptibility to oxidative damage [24,42]. Spg7 knock-out
mice showed a defect in ATP synthesis only at 23–26 months of age
[34]. Reduction of the levels of complexes I and III were observed in
mitochondria isolated from brain of Afg3l2 −/− mice or from
cerebellum and spinal cord of Spg7−/− Afg3l2Emv66/+ mice [35,38].
In the last model, instability of respiratory complexes rather than
decreased assembly suggested a peculiar alteration of the mitochon-
drial membranes. This would also be consistent with the tendency
of mitochondria with reduced levels of m-AAA protease subunits to
lose mt-DNA [38]. In conclusion, many independent data suggest that
m-AAA protease-depleted mitochondria have a mild impairment of
respiratory function. This mild impairment may become however
extremely relevant in situations of high metabolic demands or in
cellular districts where energy production should rapidly adapt to cell
function, without the possibility of fast mitochondrial protein replen-
ishment and turnover as it happens in synaptic terminals or dendritic
spines of neurons.
Understanding the cause for the alteration of mitochondrial
morphology and function is crucial to unravel the ﬁrst molecular steps
of the pathogenic process. Both incomplete removal of misfolded
Fig. 3. Possible pathogenic pathways associated with dysfunctional m-AAA proteases. Mutations or depletion of m-AAA protease subunits can lead to neurodegeneration through
several mechanisms, including accumulation of misfolded polypeptides; decreased mitochondrial protein synthesis, due to impaired processing of MRPL32; abnormal mitochondria
dynamics, via OPA1; defective mitochondrial transport; mt-DNA depletion; respiratory deﬁciency owing to reduced assembly and stability of complexes I and III.
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mitochondrial dynamics and/or the membrane structure might be
postulated. Accumulation of misfolded polypeptides inm-AAA protease
deﬁcient mitochondria has not been formally demonstrated yet.
Moreover, our knowledge on the endogenous neuronal substrates of
the m-AAA protease is still rather limited. The only substrate so far
identiﬁed that is unambigously cleaved by both the yeast and the
mammalianm-AAA protease is themitochondrial ribosome component
MRPL32 [18]. ImpairmentofMRPL32processing and accumulation of its
precursor has been found in the liver of paraplegin-deﬁcient mice [18].
Furthermore, accumulation of the MRPL32 precursor was observed in
cerebellar mitochondria of Spg7−/− Afg3l2Emv66/+mice (P.M. and E.I.R.,
unpublished observations). However, sufﬁcient mature MRPL32 is still
present in these mitochondria and no defects of mitochondrial protein
synthesis have beenobserved inAfg3l2nullmutants [35]. This result can
be explained by the efﬁcient cleavage of MRPL32 from the residual
AFG3L1-containingm-AAA protease, or by the presence of a redundant
protease inmammals. So it appears unlikely that abnormal processing of
MRPL32 underlies neurodegeneration. Recent studies have suggested
that the m-AAA protease may process OPA1 [43,44]. OPA1 is a
particularly appealing substrate since it has a role in mitochondrial
fusion, cristae morphology, and protection from apoptosis [45–49] and
anOPA1-mediated pathogenic pathway could potentially explainmany
aspects of the observed phenotypes.Moreover, OPA1 itself ismutated in
a human neurodegenerative disease [50]. The implications and
controversy surrounding this ﬁnding is discussed extensively in the
next chapter.
3. Processing of OPA1, mutated in autosomal dominant optic
atrophy, by mitochondrial proteases
Besides exerting a crucial role in quality control of mitochondrial
proteins, mitochondrial proteases cleave speciﬁc substrates, allowing
their maturation, and thereby controlling a number of tasks. OPA1 is a
key regulator of mitochondrial function, whose activity strictly
depends on regulated or induced processing. As its yeast homolog,
Mgm1, OPA1 is a dynamin-like GTPase involved in mitochondrial
inner membrane fusion. In addition, mammalian OPA1 plays a crucialrole in the regulation of mitochondrial cristae morphology, and in
protecting cells from apoptosis [45–49].
OPA1 is mutated in autosomal dominant optic atrophy (ADOA), a
progressive neurological disease characterized by degeneration of the
retinal ganglion cells and atrophy of the optic nerve [51,52]. Recently,
the spectrum of OPA1-associated neurological conditions has expanded
to include atypical clinical presentations and the so called “OPA1 plus”
phenotype, in which optic atrophy associates with chronic progressive
ophtalmoplegia, ataxia, sensironeuronal deafness, sensory-motor neu-
ropathy and myopathy, and with mt-DNA multiple deletions [53]. The
spectrum of OPA1 mutations in patients covers almost the entire gene,
and ranges frommissensemutations to loss-of-function alleles, strongly
suggesting that haploinsufﬁciency is at the basis of the disease. Cell lines
fromOPA1patients have a fragmentedmitochondrial network, pointing
to impairment of mitochondrial dynamics in the degenerative process
[53].
OPA1 resides in the mitochondrial intermembrane space, in tight
association with the membrane. Mitochondria contain various mature
OPA1 isoforms that arise through the combinations of alternative
splicing events (eight alternative OPA1 transcripts have been described
in humans) and proteolytic maturation [43,44,54]. All OPA1 protein
variants contain a mitochondrial targeting sequence, followed by a
transmembrane segment, the GTPase dynamin-like domain, a central
domain of unknown function, and a C-terminal coiled coil region.
Alternative splicing involves exons 4, 4b, and 5b that can be present or
absent from the transcript in different combinations. Interestingly,
exons 4b and 5b are vertebrate speciﬁc, and encode for additional
hydrophobic stretches. Several evidences suggest that the pro-fusion
and the anti-apoptotic activities of OPA1 are distinct and independent
from each other and can be ascribed to different isoforms [55]. OPA1
variants containing exon 4 are required to maintain the mitochondrial
network fusion ability. In contrast, OPA1 isoforms containing exon 5b
appear to be dispensable for maintenance of a fused mitochondrial
network, but are crucial for the anti-apoptotic role.
After removal of the mitochondrial targeting sequence by the
mitochondrial processing peptidase (MPP), long OPA1 isoforms can
undergo additional cleavage events at sites S1 and S2 to generate
shorter isoforms, lacking the ﬁrst transmembrane domain, which are
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OPA1 transcripts encode polypeptides containing the S1 cleavage site
located in exon 5, while only transcripts containing exon 5b bear the
S2 site in addition. As result of this complex transcriptional and post-
translation regulation, in most human and murine tissues, ﬁve main
OPA1 forms are recognizable, two long membrane-bound OPA1
isoforms (L1 and L2) and three short soluble ones (S3–5) (Fig. 4A).Fig. 4. OPA1 undergoes proteolytic cleavage under physiological and stress conditions.
A. In physiological conditions, most tissues express two OPA1 splicing variants (variant
1 and 7), which differ for the absence or presence of exon 5b, respectively. Both variants
are ﬁrst processed by the matrix metallopeptidase (MPP) that removes the
mitochondrial targeting signal (MTS) and then by AAA proteases that lead to the
formation of long and short OPA1 isoforms in similar amounts. The m-AAA protease
cleaves OPA1 at site S1, located in exon 5. The i-AAA protease instead cleaves OPA1 at
S2 within exon 5b. As a result, ﬁve main isoforms of OPA1 are produced, L1 and L2, and
S3-5. B. Under stress conditions, when ATP levels are low, a yet to be identiﬁed protease
cleaves OPA1 at S1 and accumulates short OPA1 isoforms.OPA1 processing is a key step for its function. A combination of
long and short OPA1 isoforms is required for proper mitochondrial
fusion [57]. Interestingly, all OPA1 isoforms containing exon 4b are
efﬁciently processed and are not able to rescue fusion defects of OPA1
null MEF. On the other hand, OPA1 fusion-competent isoforms appear
to be only partially processed and to produce a combination of long
and short variants in approximately equimolar amount [57]. OPA1
complexes composed of soluble short isoforms andmembrane-bound
long isoforms mediate tightening of cristae junctions and protect cells
from apoptosis [45].
The relevance of OPA1 processing for ADOA pathogenesis is still
unclear, since in most cases patients carry heterozygous mutations
that reduce the total level of the protein but do not impair processing.
However, several pathological conditions have been linked to
abnormal OPA1 processing: low mitochondrial ATP levels, membrane
potential dissipation, and apoptosis induction stimulate OPA1
processing leading to the disappearance of long OPA1 variants and
the accumulations of short stable isoforms [43,58]. This so-called
inducible OPA1 processing may play a protective role in several
conditions characterized by mitochondrial dysfunction, by leading to
mitochondrial fragmentation and preventing fusion of dysfunctional
organelles with the functional network. Notably, increased OPA1
processing was observed in a cybrid cell line of a patient with MERRF
syndrome, a severe mitochondrial myopathy associated with muta-
tions in themt-DNA, in ﬁbroblasts from themutatormouse, carrying a
mutation in the proof-reading domain of the mitochondrial polymer-
ase gamma and thereby accumulating mt-DNA mutations, and ﬁnally
in the heart of a heart-speciﬁc knock-out of the TFAM transcription
factor [56]. Induced OPA1 processing can be prevented by incubation
with o-phenanthroline, ametalloprotease inhibitor, and zinc, whereas
it is stimulated by iron [43,56,58].
Increased OPA1 processing in absence of a measurable mitochon-
drial dysfunction or alteration of membrane potential occurred in
Prohibitin-2 KO cells [59]. These cells had abnormal mitochondria with
absent lamellar shaped cristae and accumulation of vesicular shaped
cristae. Moreover, they displayed an increased susceptibility to a wide
range of apoptotic stimuli. These phenotypes could be rescued by the
expression of a long uncleavable OPA1 isoform, demonstrating that
prohibitins regulate mitochondrial morphology through OPA1. The
prohibitins are large ring-shaped complexes in the inner membrane,
composed of two homologous and interdependent subunits, with a
putative membrane scaffolding function [60]. In yeast they form a
supercomplex together with the m-AAA protease, and negatively
regulate its activity [61]. The lack of prohibitins may therefore increase
the activity of this and other mitochondrial proteases.
The identiﬁcation of the protease or proteases implicated in
regulating OPA1 processing has received great attention in the last
few years, but has remained somewhat elusive. The i-AAA protease
YME1L was found to regulate OPA1 cleavage at S2 in downregulation
experiments [57,62] (Fig. 4A). This cleavage site is present in alternative
splice forms important for the anti-apoptotic OPA1 function. Debate
instead still exists about themammalian protease responsible for OPA1
cleavage at S1.
PARL is a mitochondrial rhomboid-like protease located in the inner
mitochondrial membrane, with seven membrane-spanning regions
(Fig. 1A, B). As other rhomboids, PARL is an intramembrane serine
protease. Since the S. cerevisiae mitochondrial rhomboid Pcp1 is the
protease responsible formaturation ofMgm1 [63], PARLwas considered
a prime candidate for mediating OPA1 cleavage. Albeit sequence and
functional homology between Mgm1 and OPA1, the yeast and the
mammalian systems display consistent differences. Neither Pcp1 nor
PARL affect processing of OPA1 in yeast, although yeast cells are able to
conduct proteolytic processing of OPA1 [44]. Moreover, OPA1 proces-
sing occurs normally in rhomboid-7 (the PARL homolog) Drosophila
mutants and was even slightly enhanced in MEF derived from Parl
knock-out mice [62,64].
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processing at the S1 site [43,44] (Fig. 4A). The formation of OPA1 short
isoforms is in fact impaired in yeast cells lacking the m-AAA subunits,
but is restored upon expression of the mammalian protease. Interest-
ingly, the homo-oligomeric AFG3L2 or AFG3L1 isoenzymes appear to be
more efﬁcient than the hetero-oligomeric paraplegin-containing com-
plex [44]. Although overexpression of paraplegin in mammalian cells
stimulate OPA1 processing, paraplegin-deﬁcient cell lines and tissues
show normal OPA1 processing, consistent with the redundant role of
the homo-oligomeric complex [43,44]. It cannot be excluded, however,
that absence of paraplegin affects OPA1 processing in a subset of
mitochondria located distally in long axons, explaining the speciﬁc
phenotype observed in themouse model. Due to technical reasons, this
hypothesis is difﬁcult to test. A possible role of the m-AAA protease in
OPA1 cleavage opens up the intriguing possibility that the diseases
linked to paraplegin and AFG3L2 may in part be due to impairment of
regulated processing of this crucial GTPase.
Although several data are consistent with a role of the ATP-
dependent m- and i-AAA proteases in the regulated cleavage of OPA1
molecules, it is unlikely that they might be implicated in processing
OPA1 in conditions of mitochondrial stress associated with decreased
ATP levels. It is instead conceivable that another yet to be identiﬁed
protease might account for the inducible OPA1 cleavage (Fig. 4B). The
identiﬁcation of this protease will certainly shed new light on a very
important pathway by which mitochondria respond to energy
dysfunction, apoptotic stimuli and membrane potential dissipation.
4. Mitochondrial proteases protect neurons from apoptotic death:
HTRA2/OMI and PARL
Two other mitochondrial proteases have received great attention
in the last few years for their potential role in neurodegeneration: the
HRTA2/OMI and the PARL proteases. They will be here discussed
together because of some similarities in the way they affect neuronal
cell death and of a recently discovered functional connection between
them.
HTRA2/OMI is a mitochondrial serine protease, homologous to the
bacterial HtrA stress responsive genes, DegP and DegS (for extensive
review see [65]). DegP acts as a chaperone at normal temperatures but
exerts non-selective proteolytic activity against misfolded polypetides
in the periplasmic space at high temperatures, while DegS cleaves a
speciﬁc substrate to initiate a transcriptional stress-response [66,67].
The mammalian HTRA2 is a trimer characterized by an N-terminal
mitochondrial targeting sequence, followed by a transmembrane
domain, an inhibitor of apoptosis (IAP)-binding motif (IBM), a
trypsin-like protease domain, and a C-terminal PDZ domain (Fig. 1A).
HTRA2 is attached to the inner mitochondrial membrane by the
transmembrane domain and resides in the intermembrane space [68]
(Fig. 1B). The protease activity of HTRA2has been assessed in vitro using
β-casein as a substrate. In this assay, the absence of the PDZ domain or
the presence of peptides that bind the PDZ domain, signiﬁcantly
augments HTRA2 proteolytic activity, suggesting a regulatory role for
this domain [69,70]. It is worth stressing that whether HTRA2 has a
protease and/or chaperone activity within mitochondria under phys-
iological or stress conditions is largely unclear. The endogenous
substrates of HTRA2 in the mitochondria are still unknown. Recently,
loss of HTRA2 has been shown to result in the accumulation of unfolded
proteins in the mitochondria, with defective respiration and enhanced
production of reactive oxygen species [71].
Upon mitochondrial import, HTRA2 is further processed into a
more soluble form that is devoid of the transmembrane domain and
exposes the IBM domain in the N-terminal part (Fig. 1B). This domain
is homologous to those found in the Drosophila IAP inhibitors Reaper,
Hid and Grim, and the mammalian Smac/Diablo. Upon apoptotic
stimuli, HTRA2 is released from the mitochondria and binds to IAPs,
inactivating their caspase-inhibitor activity. Consistently, RNA inter-ference of HTRA2 increased the resistance of cell lines against
apoptotic stimuli [72–76].
The pro-apoptotic role of HTRA2 was questioned when a
spontaneous mutation in the murine Htra2 gene was found to be at
the basis of the mnd2 mutant mouse [77,78]. These mice displayed a
progressive neurodegenerative phenotype, characterized by abnor-
mal gait, ataxia, repetitive movements and akinesis. The mutation in
the mnd2 mouse is a homozygous S276C substitution, which affects
the proteolytic activity of the protein using the β-casein assay. These
data strongly indicate that a mutation inactivating the protease
activity of HTRA2 does not induce resistance to apoptosis, but rather
increases neuronal death. A virtually identical phenotype was later
reported for mice carrying a targeted deletion of most of the coding
region, producing a complete loss-of-function allele [79]. Cells derived
from this mouse model had an increased susceptibility to cell death
stimuli. Moreover, mitochondria from HTRA2-deﬁcient mouse em-
bryonic ﬁbroblasts showed an increased susceptibility to mitochon-
drial stress and calcium-induced permeability transition and
mitochondrial membrane permeabilization [78,79].
Thus, mouse genetics shifted the focus towards an important role of
HTRA2 in neurodegeneration. The phenotypic characterization ofmnd2
and Htra2 knock-out mice showed a peculiar pattern of neuronal loss.
The brain regionmost affected by lack of HTRA2was the striatum. Focal
loss of neurons, reactive astrogliosis, and occasional apoptotic cellswere
described, together with a selective loss of terminals in the nigrostriatal
pathway [78–80]. No loss of dopaminergic neurons in the substantia
nigra was however detected [79]. Neurodegenerationwas also found in
other brain regions, in thebrainstem, in the cerebellum, and in the spinal
motoneurons. In addition, Htra2 knock-out mice showed a dramatic
decrease of the size of heart, thymus and spleen [78–80].
Interestingly, a very similar phenotype was described for mice
lacking PARL [81]. Parl knock-out mice show degeneration of striatal
and thalamic neurons, lymphocyte loss in the thymus and spleen,
growth retardation and cachexia. This phenotype can be ascribed to
massive apoptosis, without a substantial impairment of respiratory
function [81]. Parl−/− cells were susceptible to a series of intrinsic
apoptotic stimuli, released cytochrome c faster than control cells, and
failed to be protected against apoptosis by OPA1 expression [81]. Thus
two proteases, PARL and HTRA2/Omi seem to protect striatal neurons
and lymphocytes from apoptotic cell death.
A possible link between these two proteases was given by the
ﬁnding of a common interactor, the BCL2-family related mitochon-
drial protein HAX1 [82]. These interactions facilitate the mitochon-
drial processing of HTRA2 by PARL [82]. Again, mice lacking HAX1
showed striatal neurodegeneration, loss of lymphocytes in thymus
and spleen, and increased apoptosis [82]. In Drosophila, the
rhomboid-7 protease (the PARL orthologue) has also been involved
in Htra2/Omi cleavage, stressing a direct link between these two
proteases [64]. All together, these data strengthen the concept that
mitochondrial proteases, through regulation of speciﬁc substrates or
via quality control mechanisms in response to stress, play a key role
for protecting neurons from apoptotic death.
The akinesia of HTRA2-deﬁcient mice and mnd2 mutants, together
with the involvement of nigrostriatal connections, fostered the idea of a
possible link between the protease and Parkinson disease (PD).
Parkinson disease is one of the most common neurodegenerative
diseases in theagingpopulation. It is characterizedby the clinical triadof
rigidity, bradikinesia, and tremor, and by the neuropathological loss of
dopaminergic neurons in the substantia nigra with typical intracyto-
plasmatic ubiquitin- and α-synuclein positive inclusions, the Lewy
bodies. Although in largepart sporadic, a number of PARK loci havebeen
involved in rare inherited forms of the disease [83]. The HTRA2–
Parkinson disease connection is still a matter of debate, since different
studies have supported or rejected the hypothesis of a functional
association. Genetic data and a functional link between HTRA2 and
PINK1, a mitochondrial kinase responsible for an autosomal recessive
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These conﬂicting studies are summarized in Table 1. HTRA2 has been
found as a component of α-synuclein-containing inclusions in brains
with PD, dementia with Lewy bodies, and multiple-system atrophy
[84,85].
Recently, one study has shown a role of Drosophila rhomboid-7 in
proteolytic cleavage of PINK1, a maturation event required for the
production of a soluble cytoplasmic released form [64]. Although so
far there is no evidence for conservation of this process in humans,
this result highlights once again the complex interactions existing
between mitochondrial proteases and molecules involved in neuro-
degenerative phenotypes.5. Common themes and future perspectives
Increasing evidence highlights the protective role of mitochondrial
proteases against axonal degeneration and neuronal death. Proteolytic-
dependent quality control and protein processing is subject to special
challenges and demands in neurons, due to their strict requirement for
mitochondrial ATP production and Ca++ buffering, and to the need of
rapid response to changing local physiological conditions. Owing to the
extreme polarized organization of neurons, dysfunctional, old mito-
chondria located at a great distance from the cell body presumably need
to be retrogradely transported to import newly synthesized proteins, or
to be eliminated by mitophagy. Neurons are thus highly dependent on
efﬁcient intra-organellar systems, which deal with protein misfolding
and unbalance of protein synthesis, and allow the immediate local
regulation of the mitochondrial proteome in response to functional
needs. Although the neuronal selectivity observed in several of the
discussed pathologies is still a missing piece of the puzzle, strikingly the
neurons that are more sensitive to defective proteolytic function are
those with longer axons, the most elaborate dendritic trees, or special
arrangement ofmitochondrial distribution, such as the optic nerve [86],Table 1
Contradictory studies on the role of HTRA2 in Parkinson disease.
In favor Against
Genetic evidence
in human patients
A141S polymorphism in
HTRA2 associated with
sporadic PD (414 PD
patients of German origin
and 331 healthy controls);
G399S mutation found in
PD patients (518 PD
patients, 370 controls) [84].
No association between
the A141S polymorphism
and PD; G399S change also
found in normal controls at
the same frequency (644
PD cases and 828 North
American normal controls)
[91].
R404W mutation found in
PD patients; a number of
mutations were found in
regulatory regions of the
gene only in PD patients
and not controls (266
Belgian PD patients, 273
controls [90].
No pathogenic HTRA2
variants found in a study
on a Poland populations of
95 PD probands [92].
Functional link between
HTRA2 and PINK1
In Drosophila, PINK1
overexpression phenotype
is partially suppressed by
loss of HtrA2 [64]; while
HtrA2 overexpression can
partially substitute for loss
of PINK1 [93].
Genetic analysis in
Drosophila does not
support function of HtrA2
and PINK1 in the same
pathway [95].
HTRA2 is phosphorylated
by the p38 pathway in a
PINK-1 dependent
manner. Phosphorylated
HTRA2 is increased in the
brain of sporadic PD
patients, and decreased in
PINK1 mutated patients
[94].again emphasizing the strict relation existing in neurons between
function and distribution of mitochondria.
As illustrated by the previous examples, proteases may be directly
mutated in neurodegenerative diseases, may increase the susceptibility
of neurons to apoptotic cell death, and may regulate mitochondrial
proteinswhich in turnare involved inneurodegenerative phenotypes or
in mitochondrial dysfunction. The elucidation of these pathways has
important implications for the disclosure of pathogenic pathways in
speciﬁc neurodegenerative diseases, and for future therapeutic strate-
gies. For example, the identiﬁcationof theprotease responsible forOPA1
induced processing in conditions of low ATP production may pave the
way to treatments with a potential impact in a broad collection of
pathologies characterized by mitochondrial dysfunction. Moreover, the
identiﬁcation of speciﬁc substrates of them-AAA proteasesmay provide
novel therapeutic targets for the associated diseases.
A still, rather unexplored ﬁeld is the involvement of mitochondrial
proteases in themitochondrial unfolded protein response (mtUPR), in
which the accumulation of unfolded proteins in the mitochondrial
matrix results in the transcriptional upregulation of nuclear genes
encoding mitochondrial stress proteins [87]. Among these are Yme1,
the component of the i-AAA protease, and ClpP, a matrix ATP-
dependent protease [88]. Upregulation of the levels of the ClpP and
Lon ATP-dependent proteases occurs in the heart of a Friedreich ataxia
heart-speciﬁc conditional mouse model [89]. The expression and the
stability of mitochondrial proteases may therefore modulate the
phenotype of several neurodegenerative conditions associated to
impaired mitochondrial function.
In conclusion, mitochondrial proteases are emerging as important
actors on the stage of mitochondrial function and dysfunction in
neurons, and as attractive therapeutic targets for the prevention of
neuronal cell death and axonal degeneration.
Note added in proof
Late-onset cerebellar degeneration in mice heterozygous for
Afg3l2 has been recently reported (Maltecca F., Magnoni R., Cerri F.,
Cox G.A., Quattrini A., Casari G. J. Neurosci., 2009, 29:9244–9254).
Acknowledgements
We wish to thank Franco Taroni for sharing unpublished observa-
tions, and Thomas Langer for many stimulating discussions. This work
was supported by grants from the UMDF, MDA, and CARIPLO
foundations.
References
[1] M.P. Mattson, M. Gleichmann, A. Cheng, Mitochondria in neuroplasticity and
neurological disorders, Neuron 60 (2008) 748–766.
[2] O. Kann, R. Kovacs, Mitochondria and neuronal activity, Am. J. Physiol., Cell Physiol.
292 (2007) C641–C657.
[3] D.C. Chan, Mitochondria: dynamic organelles in disease, aging, and development,
Cell 125 (2006) 1241–1252.
[4] P.J. Hollenbeck, W.M. Saxton, The axonal transport of mitochondria, J. Cell Sci. 118
(2005) 5411–5419.
[5] J.Q. Kwong, M.F. Beal, G. Manfredi, The role of mitochondria in inherited
neurodegenerative diseases, J. Neurochem. 97 (2006) 1659–1675.
[6] M.F. Beal, Mitochondria and neurodegeneration, Novartis Found. Symp. 287
(2007) 183–192 (discussion 192–186).
[7] M.T. Ryan, N.J. Hoogenraad, Mitochondrial–nuclear communications, Annu. Rev.
Biochem. 76 (2007) 701–722.
[8] W. Voos, K. Rottgers, Molecular chaperones as essential mediators of mitochon-
drial biogenesis, Biochim. Biophys. Acta 1592 (2002) 51–62.
[9] T. Tatsuta, T. Langer, Quality control of mitochondria: protection against
neurodegeneration and ageing, EMBO J. 27 (2008) 306–314.
[10] H. Arlt, R. Tauer, H. Feldmann, W. Neupert, T. Langer, The YTA10–12 complex, an
AAA protease with chaperone-like activity in the inner membrane of mitochon-
dria, Cell 85 (1996) 875–885.
[11] S. Banﬁ, M.T. Bassi, G. Andolﬁ, A. Marchitiello, S. Zanotta, A. Ballabio, G. Casari, B.
Franco, Identiﬁcation and characterization of AFG3L2, a novel paraplegin-related
gene, Genomics 59 (1999) 51–58.
9P. Martinelli, E.I. Rugarli / Biochimica et Biophysica Acta 1797 (2010) 1–10[12] G. Casari, M. De Fusco, S. Ciarmatori, M. Zeviani, M. Mora, P. Fernandez, G. De
Michele, A. Filla, S. Cocozza, R. Marconi, A. Dürr, B. Fontaine, A. Ballabio, Spastic
paraplegia and OXPHOS impairment caused bymutations in paraplegin, a nuclear-
encoded mitochondrial metalloprotease, Cell 93 (1998) 973–983.
[13] A.F. Neuwald, L. Aravind, J.L. Spouge, E.V. Koonin, AAA+: A class of chaperone-like
ATPases associated with the assembly, operation, and disassembly of protein
complexes, Genome Res. 9 (1999) 27–43.
[14] K. Leonhard, B. Guiard, G. Pellecchia, A. Tzagoloff, W. Neupert, T. Langer,
Membrane protein degradation by AAA proteases in mitochondria: extraction of
substrates from either membrane surface, Mol. Cell 5 (2000) 629–638.
[15] T. Tatsuta, S. Augustin, M. Nolden, B. Friedrichs, T. Langer, m-AAA protease-driven
membrane dislocation allows intramembrane cleavage by rhomboid in mito-
chondria, EMBO J. 26 (2007) 325–335.
[16] K. Leonhard, J.M. Herrmann, R.A. Stuart, G. Mannhaupt, W. Neupert, T. Langer, AAA
proteases with catalytic sites on opposite membrane surfaces comprise a
proteolytic system for the ATP-dependent degradation of inner membrane
proteins in mitochondria, EMBO J. 15 (1996) 4218–4229.
[17] H. Arlt, G. Steglich, R. Perryman, B. Guiard, W. Neupert, T. Langer, The formation of
respiratory chain complexes in mitochondria is under the proteolytic control of
the m-AAA protease, EMBO J. 17 (1998) 4837–4847.
[18] M. Nolden, S. Ehses, M. Koppen, A. Bernacchia, E.I. Rugarli, T. Langer, The m-AAA
protease defective in hereditary spastic paraplegia controls ribosome assembly in
mitochondria, Cell 123 (2005) 277–289.
[19] M. Koppen, M.D. Metodiev, G. Casari, E.I. Rugarli, T. Langer, Variable and tissue-
speciﬁc subunit composition of mitochondrial m-AAA protease complexes linked
to hereditary spastic paraplegia, Mol. Cell. Biol. 27 (2007) 758–767.
[20] A.E. Harding, Hereditary “pure” spastic paraplegia, The hereditary ataxias and
related disorders, Churchill Livingstone, New York, 1984, pp. 174–191.
[21] J.K. Fink, Hereditary spastic paraplegia, Curr. Neurol. Neurosci. Rep. 6 (2006) 65–76.
[22] N. Elleuch, C. Depienne, A. Benomar, A.M. Hernandez, X. Ferrer, B. Fontaine, D.
Grid, C.M. Tallaksen, R. Zemmouri, G. Stevanin, A. Durr, A. Brice, Mutation analysis
of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia,
Neurology 66 (2006) 654–659.
[23] F. Brugman, H. Scheffer, J.H. Wokke, W.M. Nillesen, M. de Visser, E. Aronica, J.H.
Veldink, L.H. van den Berg, Paraplegin mutations in sporadic adult-onset upper
motor neuron syndromes, Neurology 71 (2008) 1500–1505.
[24] A. Arnoldi, A. Tonelli, F. Crippa, G. Villani, C. Pacelli, M. Sironi, U. Pozzoli, M.G.
D'Angelo, G. Meola, A. Martinuzzi, C. Crimella, F. Redaelli, C. Panzeri, A. Renieri, G.P.
Comi, A.C. Turconi, N. Bresolin, M.T. Bassi, A clinical, genetic, and biochemical
characterization of SPG7 mutations in a large cohort of patients with hereditary
spastic paraplegia, Human Mutat. 29 (2008) 522–531.
[25] C.J. McDermott, R.K. Dayaratne, J. Tomkins, M.E. Lusher, J.C. Lindsey, M.A. Johnson, G.
Casari, D.M. Turnbull, K. Bushby, P.J. Shaw, Paraplegin gene analysis in hereditary
spastic paraparesis (HSP) pedigrees in northeast England, Neurology 56 (2001)
467–471.
[26] P.A. Wilkinson, A.H. Crosby, C. Turner, L.J. Bradley, L. Ginsberg, N.W. Wood, A.H.
Schapira, T.T. Warner, A clinical, genetic and biochemical study of SPG7 mutations
in hereditary spastic paraplegia, Brain 127 (2004) 973–980.
[27] T.Warnecke, T. Duning, A. Schwan, H. Lohmann, J.T. Epplen, P. Young, A novel form
of autosomal recessive hereditary spastic paraplegia caused by a new SPG7
mutation, Neurology 69 (2007) 368–375.
[28] C. Tzoulis, P.S. Denora, F.M. Santorelli, L.A. Bindoff, Hereditary spastic paraplegia
caused by the novel mutation 1047insC in the SPG7 gene, J. Neurol. 255 (2008)
1142–1144.
[29] C. Cagnoli, G. Stevanin, A. Durr, P. Ribai, S. Forlani, A. Brussino, P. Pappi, L. Pugliese,
M. Barberis, R.L. Margolis, S.E. Holmes, S. Padovan, N. Migone, D. Di Bella, F. Taroni,
A. Brice, A. Brusco, Mutations in AFG3L2 gene (SCA28) in autosomal dominant
cerebellar ataxias, presented at the Annual meeting of the American Society of
Human Genetics, Philadelphia, Pennsylvania, 2008.
[30] D. DiBella, F. Lazzaro, A. Brusco, G. Battaglia, P.A.A. Finardi, V. Fracasso, M. Plumari,
C. Cagnoli, F. Tempia, A. Brussino, C. Gellera, C. Mariotti, P. Plevani, S. DiDonato, T.
Langer, M. Muzi-Falconi, F. Taroni, AFG3L2 mutations cause autosomal dominant
ataxia SCA28 and reveal an essential role of the m-AAA AFG3L2 homocomplex in
the cerebellum, presented at the Annual meeting of the American Society of
Human Genetics, Philadelphia, Pennsylvania, 2008.
[31] F. Taroni, S. DiDonato, Pathways to motor incoordination: the inherited ataxias,
Nat. Rev., Neurosci. 5 (2004) 641–655.
[32] C. Cagnoli, C. Mariotti, F. Taroni, M. Seri, A. Brussino, C. Michielotto, M. Grisoli, D. Di
Bella, N. Migone, C. Gellera, S. Di Donato, A. Brusco, SCA28, a novel form of
autosomal dominant cerebellar ataxia on chromosome 18p11.22–q11.2, Brain 129
(2006) 235–242.
[33] C. Mariotti, A. Brusco, D. Di Bella, C. Cagnoli, M. Seri, C. Gellera, S. Di Donato, F.
Taroni, Spinocerebellar ataxia type 28: a novel autosomal dominant cerebellar
ataxia characterized by slow progression and ophthalmoparesis, Cerebellum 7
(2008) 184–188.
[34] F. Ferreirinha, A. Quattrini, M. Pirozzi, V. Valsecchi, G. Dina, V. Broccoli, A.
Auricchio, F. Piemonte, G. Tozzi, L. Gaeta, G. Casari, A. Ballabio, E.I. Rugarli, Axonal
degeneration in paraplegin-deﬁcient mice is associated with abnormal mito-
chondria and impairment of axonal transport, J. Clin. Invest. 113 (2004) 231–242.
[35] F. Maltecca, A. Aghaie, D.G. Schroeder, L. Cassina, B.A. Taylor, S.J. Phillips, M.
Malaguti, S. Previtali, J.L. Guenet, A. Quattrini, G.A. Cox, G. Casari, Themitochondrial
protease AFG3L2 is essential for axonal development, J. Neurosci. 28 (2008)
2827–2836.
[36] L.W. Duchen, S. Gomez, J.L. Guénet, S. Love, Paralysé: a new neurological mutant
mouse with progressive atrophy and loss of motor nerve terminals, J. Physiol. 345
(1983) 166P.[37] B. Blondet, M.J. Duxson, A.J. Harris, J. Melki, J.L. Guenet, M. Pincon-Raymond, F.
Rieger, Nerve and muscle development in paralyse mutant mice, Dev. Biol. 132
(1989) 153–166.
[38] P. Martinelli, V. La Mattina, A. Bernacchia, R. Magnoni, F. Cerri, G. Cox, A. Quattrini, G.
Casari, E.I. Rugarli, Genetic interaction between the m-AAA protease isoenzymes
reveals novel roles in cerebellar degeneration, Hum. Mol. Genet. 18 (2009)
2001–2013.
[39] G. Kremmidiotis, A.E. Gardner, C. Settasatian, A. Savoia, G.R. Sutherland, D.F.
Callen, Molecular and functional analyses of the human and mouse genes
encoding AFG3L1, a mitochondrial metalloprotease homologous to the human
spastic paraplegia protein, Genomics 76 (2001) 58–65.
[40] M. Pirozzi, A. Quattrini, G. Andolﬁ, G. Dina, M.C. Malaguti, A. Auricchio, E.I. Rugarli,
Intramuscular viral delivery of paraplegin rescues peripheral axonopathy in a
model of hereditary spastic paraplegia, J. Clin. Invest. 116 (2006) 202–208.
[41] C. Soderblom, C. Blackstone, Trafﬁc accidents: molecular genetic insights into the
pathogenesis of the hereditary spastic paraplegias, Pharmacol. Ther. 109 (2006)
42–56.
[42] L. Atorino, L. Silvestri, M. Koppen, L. Cassina, A. Ballabio, R. Marconi, T. Langer, G.
Casari, Loss of m-AAA protease in mitochondria causes complex I deﬁciency and
increased sensitivity to oxidative stress in hereditary spastic paraplegia, J. Cell Biol.
163 (2003) 777–787.
[43] N. Ishihara, Y. Fujita, T. Oka, K. Mihara, Regulation of mitochondrial morphology
through proteolytic cleavage of OPA1, EMBO J. 25 (2006) 2966–2977.
[44] S. Duvezin-Caubet, M. Koppen, J. Wagener, M. Zick, L. Israel, A. Bernacchia, R.
Jagasia, E.I. Rugarli, A. Imhof, W. Neupert, T. Langer, A.S. Reichert, OPA1 processing
reconstituted in yeast depends on the subunit composition of the m-AAA protease
in mitochondria, Mol. Biol. Cell 18 (2007) 3582–3590.
[45] C. Frezza, S. Cipolat, O. Martins, M. de Brito, G.V.Beznoussenko Micaroni, T. Rudka, D.
Bartoli, R.S. Polishuck, N.N. Danial, B.DeStrooper, L. Scorrano, OPA1 controls apoptotic
cristae remodeling independently from mitochondrial fusion, Cell 126 (2006)
177–189.
[46] K.L. Cerveny, Y. Tamura, Z. Zhang, R.E. Jensen, H. Sesaki, Regulation of
mitochondrial fusion and division, Trends Cell Biol. 17 (2007) 563–569.
[47] B. Westermann, Molecular machinery of mitochondrial fusion and ﬁssion, J. Biol.
Chem. 283 (2008) 13501–13505.
[48] G. Lenaers, P. Reynier, G. Elachouri, C. Soukkarieh, A. Olichon, P. Belenguer, L.
Baricault, B. Ducommun, C. Hamel, C. Delettre, OPA1 functions in mitochondria
and dysfunctions in optic nerve, Int. J. Biochem. Cell Biol. (2009), doi:10.1016/j.
biocel.2009.04.013.
[49] R. Yamaguchi, L. Lartigue, G. Perkins, R.T. Scott, A. Dixit, Y. Kushnareva, T. Kuwana,
M.H. Ellisman, D.D. Newmeyer, Opa1-mediated cristae opening is Bax/Bak and
BH3 dependent, required for apoptosis, and independent of Bak oligomerization,
Mol. Cell 31 (2008) 557–569.
[50] A. Olichon, E. Guillou, C. Delettre, T. Landes, L. Arnaune-Pelloquin, L.J. Emorine, V.
Mils, M. Daloyau, C. Hamel, P. Amati-Bonneau, D. Bonneau, P. Reynier, G. Lenaers,
P. Belenguer, Mitochondrial dynamics and disease, OPA1, Biochim. Biophys. Acta
1763 (2006) 500–509.
[51] C. Alexander, M. Votruba, U.E. Pesch, D.L. Thiselton, S. Mayer, A. Moore, M.
Rodriguez, U. Kellner, B. Leo-Kottler, G. Auburger, S.S. Bhattacharya, B. Wissinger,
OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant
optic atrophy linked to chromosome 3q28, Nat. Genet. 26 (2000) 211–215.
[52] C. Delettre, G. Lenaers, J.M. Griffoin, N. Gigarel, C. Lorenzo, P. Belenguer, L. Pelloquin, J.
Grosgeorge, C. Turc-Carel, E. Perret, C. Astarie-Dequeker, L. Lasquellec, B. Arnaud, B.
Ducommun, J. Kaplan, C.P. Hamel, Nuclear gene OPA1, encoding a mitochondrial
dynamin-relatedprotein, ismutated indominantoptic atrophy,Nat. Genet. 26 (2000)
207–210.
[53] P. Amati-Bonneau, D. Milea, D. Bonneau, A. Chevrollier, M. Ferre, V. Guillet, N.
Gueguen, D. Loiseau, M.A. Crescenzo, C. Verny, V. Procaccio, G. Lenaers, P. Reynier,
OPA1-associated disorders: phenotypes and pathophysiology, Int. J. Biochem. Cell
Biol. (2009), doi:10.1016/j.biocel.2009.04.012.
[54] V.R. Akepati, E.C. Muller, A. Otto, H.M. Strauss, M. Portwich, C. Alexander,
Characterization of OPA1 isoforms isolated from mouse tissues, J. Neurochem. 106
(2008) 372–383.
[55] A. Olichon, G. Elachouri, L. Baricault, C. Delettre, P. Belenguer, G. Lenaers, OPA1
alternate splicing uncouples an evolutionary conserved function in mitochondrial
fusion from a vertebrate restricted function in apoptosis, Cell Death Differ. 14
(2007) 682–692.
[56] S. Duvezin-Caubet, R. Jagasia, J. Wagener, S. Hofmann, A. Trifunovic, A. Hansson, A.
Chomyn, M.F. Bauer, G. Attardi, N.G. Larsson, W. Neupert, A.S. Reichert, Proteolytic
processing of OPA1 links mitochondrial dysfunction to alterations in mitochon-
drial morphology, J. Biol. Chem. 281 (2006) 37972–37979.
[57] Z. Song, H. Chen, M. Fiket, C. Alexander, D.C. Chan, OPA1 processing controls
mitochondrial fusion and is regulated bymRNA splicing, membrane potential, and
Yme1L, J. Cell Biol. 178 (2007) 749–755.
[58] L. Baricault, B. Segui, L. Guegand, A. Olichon, A. Valette, F. Larminat, G. Lenaers,
OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent
metals, Exp. Cell Res. 313 (2007) 3800–3808.
[59] C. Merkwirth, S. Dargazanli, T. Tatsuta, S. Geimer, B. Lower, F.T. Wunderlich, J.C.
von Kleist-Retzow, A. Waisman, B. Westermann, T. Langer, Prohibitins control cell
proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis
in mitochondria, Genes Dev. 22 (2008) 476–488.
[60] C. Merkwirth, T. Langer, Prohibitin function within mitochondria: essential roles for
cell proliferation and cristae morphogenesis, Biochim. Biophys. Acta 1793 (2009)
27–32.
[61] G. Steglich,W.Neupert, T. Langer, Prohibitins regulatemembraneproteindegradation
by the m-AAA protease in mitochondria, Mol. Cell. Biol. 19 (1999) 3435–3442.
10 P. Martinelli, E.I. Rugarli / Biochimica et Biophysica Acta 1797 (2010) 1–10[62] L. Griparic, T. Kanazawa, A.M. van der Bliek, Regulation of the mitochondrial
dynamin-like protein Opa1 by proteolytic cleavage, J. Cell Biol. 178 (2007) 757–764.
[63] M. Herlan, F. Vogel, C. Bornhovd, W. Neupert, A.S. Reichert, Processing of Mgm1 by
the rhomboid-type protease Pcp1 is required for maintenance of mitochondrial
morphology and of mitochondrial DNA, J. Biol. Chem. 278 (2003) 27781–27788.
[64] A.J.Whitworth, J.R. Lee, V.M.Ho, R. Flick, R. Chowdhury, G.A.McQuibban, Rhomboid-7
and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1
and Parkin, Dis Model Mech 1 (2008) 168–174 (discussion 173).
[65] L. Vande Walle, M. Lamkanﬁ, P. Vandenabeele, The mitochondrial serine protease
HtrA2/Omi: an overview, Cell Death Differ. 15 (2008) 453–460.
[66] C. Spiess, A. Beil, M. Ehrmann, A temperature-dependent switch from chaperone
to protease in a widely conserved heat shock protein, Cell 97 (1999) 339–347.
[67] N.P. Walsh, B.M. Alba, B. Bose, C.A. Gross, R.T. Sauer, OMP peptide signals initiate
the envelope-stress response by activating DegS protease via relief of inhibition
mediated by its PDZ domain, Cell 113 (2003) 61–71.
[68] T. Kadomatsu, M. Mori, K. Terada, Mitochondrial import of Omi: the deﬁnitive role
of the putative transmembrane region and multiple processing sites in the amino-
terminal segment, Biochem. Biophys. Res. Commun. 361 (2007) 516–521.
[69] L.M. Martins, B.E. Turk, V. Cowling, A. Borg, E.T. Jarrell, L.C. Cantley, J. Downward,
Binding speciﬁcity and regulation of the serine protease and PDZ domains of
HtrA2/Omi, J. Biol. Chem. 278 (2003) 49417–49427.
[70] W. Li, S.M. Srinivasula, J. Chai, P. Li, J.W. Wu, Z. Zhang, E.S. Alnemri, Y. Shi,
Structural insights into the pro-apoptotic function of mitochondrial serine
protease HtrA2/Omi, Nat. Struct. Biol. 9 (2002) 436–441.
[71] N. Moisoi, K. Klupsch, V. Fedele, P. East, S. Sharma, A. Renton, H. Plun-Favreau, R.E.
Edwards, P. Teismann, M.D. Esposti, A.D. Morrison, N.W. Wood, J. Downward, L.M.
Martins, Mitochondrial dysfunction triggered by loss of HtrA2 results in the
activation of a brain-speciﬁc transcriptional stress response, Cell Death Differ. 16
(2009) 449–464.
[72] R. Hegde, S.M. Srinivasula, Z. Zhang, R. Wassell, R. Mukattash, L. Cilenti, G. DuBois,
Y. Lazebnik, A.S. Zervos, T. Fernandes-Alnemri, E.S. Alnemri, Identiﬁcation of Omi/
HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of
apoptosis protein-caspase interaction, J. Biol. Chem. 277 (2002) 432–438.
[73] L.M. Martins, I. Iaccarino, T. Tenev, S. Gschmeissner, N.F. Totty, N.R. Lemoine, J.
Savopoulos, C.W. Gray, C.L. Creasy, C. Dingwall, J. Downward, The serine protease
Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif, J. Biol.
Chem. 277 (2002) 439–444.
[74] Y. Suzuki, Y. Imai, H. Nakayama, K. Takahashi, K. Takio, R. Takahashi, A serine
protease, HtrA2, is released from the mitochondria and interacts with XIAP,
inducing cell death, Mol. Cell 8 (2001) 613–621.
[75] A.M. Verhagen, J. Silke, P.G. Ekert, M. Pakusch, H. Kaufmann, L.M. Connolly, C.L.
Day, A. Tikoo, R. Burke, C. Wrobel, R.L. Moritz, R.J. Simpson, D.L. Vaux, HtrA2
promotes cell death through its serine protease activity and its ability to
antagonize inhibitor of apoptosis proteins, J. Biol. Chem. 277 (2002) 445–454.
[76] G. van Loo, M. van Gurp, B. Depuydt, S.M. Srinivasula, I. Rodriguez, E.S. Alnemri, K.
Gevaert, J. Vandekerckhove,W. Declercq, P. Vandenabeele, The serine protease Omi/
HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-
inhibitor XIAP and induces enhanced caspase activity, Cell Death Differ. 9 (2002)
20–26.
[77] J.M. Jones, R.L. Albin, E.L. Feldman, K. Simin, T.G. Schuster, W.A. Dunnick, J.T.
Collins, C.E. Chrisp, B.A. Taylor, M.H. Meisler, mnd2: a new mouse model of
inherited motor neuron disease, Genomics 16 (1993) 669–677.
[78] J.M. Jones, P. Datta, S.M. Srinivasula,W. Ji, S. Gupta, Z. Zhang, E. Davies, G. Hajnoczky,
T.L. Saunders,M.L. VanKeuren, T. Fernandes-Alnemri,M.H.Meisler, E.S. Alnemri, Loss
of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2
mutant mice, Nature 425 (2003) 721–727.
[79] L.M. Martins, A. Morrison, K. Klupsch, V. Fedele, N. Moisoi, P. Teismann, A. Abuin, E.
Grau, M. Geppert, G.P. Livi, C.L. Creasy, A. Martin, I. Hargreaves, S.J. Heales, H.
Okada, S. Brandner, J.B. Schulz, T. Mak, J. Downward, Neuroprotective role of theReaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice,
Mol. Cell. Biol. 24 (2004) 9848–9862.
[80] S. Rathke-Hartlieb, U. Schlomann, P. Heimann, M.H. Meisler, H. Jockusch, J.W.
Bartsch, Progressive loss of striatal neurons causes motor dysfunction in MND2
mutant mice and is not prevented by Bcl-2, Exp. Neurol. 175 (2002) 87–97.
[81] S. Cipolat, T. Rudka, D. Hartmann, V. Costa, L. Serneels, K. Craessaerts, K. Metzger, C.
Frezza, W. Annaert, L. D'Adamio, C. Derks, T. Dejaegere, L. Pellegrini, R. D'Hooge, L.
Scorrano, B. De Strooper, Mitochondrial rhomboid PARL regulates cytochrome c
release during apoptosis via OPA1-dependent cristae remodeling, Cell 126 (2006)
163–175.
[82] J.R. Chao, E. Parganas, K. Boyd, C.Y. Hong, J.T. Opferman, J.N. Ihle, Hax1-mediated
processing of HtrA2 by Parl allows survival of lymphocytes and neurons, Nature
452 (2008) 98–102.
[83] S. Lesage, A. Brice, Parkinson's disease: from monogenic forms to genetic
susceptibility factors, Hum. Mol. Genet. 18 (2009) R48–R59.
[84] K.M. Strauss, L.M. Martins, H. Plun-Favreau, F.P. Marx, S. Kautzmann, D. Berg, T.
Gasser, Z. Wszolek, T. Muller, A. Bornemann, H. Wolburg, J. Downward, O. Riess, J.B.
Schulz, R. Kruger, Loss of function mutations in the gene encoding Omi/HtrA2 in
Parkinson's disease, Hum. Mol. Genet. 14 (2005) 2099–2111.
[85] Y. Kawamoto, Y. Kobayashi, Y. Suzuki, H. Inoue, H. Tomimoto, I. Akiguchi, H. Budka,
L.M. Martins, J. Downward, R. Takahashi, Accumulation of HtrA2/Omi in neuronal
and glial inclusions in brains with alpha-synucleinopathies, J. Neuropathol. Exp.
Neurol. 67 (2008) 984–993.
[86] C.Y. Yu Wai Man, P.F. Chinnery, P.G. Grifﬁths, Optic neuropathies—importance of
spatial distribution of mitochondria as well as function, Med. Hypotheses 65
(2005) 1038–1042.
[87] Q. Zhao, J. Wang, I.V. Levichkin, S. Stasinopoulos, M.T. Ryan, N.J. Hoogenraad, A
mitochondrial speciﬁc stress response in mammalian cells, EMBO J. 21 (2002)
4411–4419.
[88] J.E. Aldridge, T. Horibe, N.J. Hoogenraad, Discovery of genes activated by the
mitochondrial unfolded protein response (mtUPR) and cognate promoter
elements, PLoS ONE 2 (2007) e874.
[89] B. Guillon, A.L. Bulteau, M.Wattenhofer-Donze, S. Schmucker, B. Friguet, H. Puccio,
J.C. Drapier, C. Bouton, Frataxin deﬁciency causes upregulation of mitochondrial
Lon and ClpP proteases and severe loss of mitochondrial Fe-S proteins, FEBS J. 276
(2009) 1036–1047.
[90] V. Bogaerts, K. Nuytemans, J. Reumers, P. Pals, S. Engelborghs, B. Pickut, E. Corsmit,
K. Peeters, J. Schymkowitz, P.P. De Deyn, P. Cras, F. Rousseau, J. Theuns, C. Van
Broeckhoven, Genetic variability in the mitochondrial serine protease HTRA2
contributes to risk for Parkinson disease, Human Mutat. 29 (2008) 832–840.
[91] J. Simon-Sanchez, A.B. Singleton, Sequencing analysis of OMI/HTRA2 shows
previously reported pathogenic mutations in neurologically normal controls,
Hum. Mol. Genet. 17 (2008) 1988–1993.
[92] O.A. Ross, A.I. Soto, C. Vilarino-Guell, M.G. Heckman, N.N. Diehl, M.M. Hulihan, J.O.
Aasly, S. Sando, J.M. Gibson, T. Lynch, A. Krygowska-Wajs, G. Opala, M.
Barcikowska, K. Czyzewski, R.J. Uitti, Z.K. Wszolek, M.J. Farrer, Genetic variation
of Omi/HtrA2 and Parkinson's disease, Parkinsonism Relat. Disord. 14 (2008)
539–543.
[93] L.S. Tain, R.B. Chowdhury, R.N. Tao, H. Plun-Favreau, N. Moisoi, L.M. Martins, J.
Downward, A.J. Whitworth, N. Tapon, Drosophila HtrA2 is dispensable for
apoptosis but acts downstream of PINK1 independently from Parkin, Cell Death
Differ. (2009).
[94] H. Plun-Favreau, K. Klupsch, N. Moisoi, S. Gandhi, S. Kjaer, D. Frith, K. Harvey, E.
Deas, R.J. Harvey, N. McDonald, N.W. Wood, L.M. Martins, J. Downward, The
mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated
kinase PINK1, Nat. Cell Biol. 9 (2007) 1243–1252.
[95] J. Yun, J.H. Cao, M.W. Dodson, I.E. Clark, P. Kapahi, R.B. Chowdhury, M. Guo, Loss-
of-function analysis suggests that Omi/HtrA2 is not an essential component of the
PINK1/PARKIN pathway in vivo, J. Neurosci. 28 (2008) 14500–14510.
